MetaVia Inc. Q1 2025 10-Q Filed

Ticker: MTVA · Form: 10-Q · Filed: May 14, 2025 · CIK: 1638287

Metavia INC. 10-Q Filing Summary
FieldDetail
CompanyMetavia INC. (MTVA)
Form Type10-Q
Filed DateMay 14, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

TL;DR

MetaVia Inc. 10-Q filed for Q1 2025. Financials look stable.

AI Summary

MetaVia Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc., is based in Cambridge, MA. The filing covers the first quarter of 2025 and includes financial data such as common stock, additional paid-in capital, and retained earnings as of March 31, 2025, and December 31, 2024.

Why It Matters

This filing provides a snapshot of MetaVia Inc.'s financial health and position at the end of the first quarter of 2025, crucial for investors and stakeholders to assess the company's performance.

Risk Assessment

Risk Level: low — This is a routine quarterly filing providing standard financial information without immediate red flags.

Key Numbers

Key Players & Entities

FAQ

What was MetaVia Inc.'s former name before NeuroBo Pharmaceuticals, Inc.?

MetaVia Inc. was formerly known as Gemphire Therapeutics Inc. before becoming NeuroBo Pharmaceuticals, Inc.

What is the SIC code for MetaVia Inc.?

The Standard Industrial Classification code for MetaVia Inc. is 2834, Pharmaceutical Preparations.

When was the name change from Gemphire Therapeutics Inc. to NeuroBo Pharmaceuticals, Inc.?

The date of the name change from Gemphire Therapeutics Inc. was 20150331.

What is the business address of MetaVia Inc.?

The business address of MetaVia Inc. is 545 Concord Avenue, Suite 210, Cambridge, MA 02138.

What is the filing date of this 10-Q report?

This 10-Q report was filed on 20250514.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding MetaVia Inc. (MTVA).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing